Oncology development
What SITC 2026 showed about brenetafusp plus tebentafusp in uveal melanoma
What Immunocore’s Phase 1/2 uveal melanoma data showed about survival and safety, and what the planned randomized trial can clarify.
By Lampgen Clinical Research

3 min read · estimated
What the source reported
Immunocore reported an estimated 70% two-year overall survival rate in 17 evaluable first-line patients with HLA-A*02:01-positive metastatic uveal melanoma who received brenetafusp plus tebentafusp. The company presented the Phase 1/2 findings at SITC on November 6, 2026, using a June 2026 data cutoff. The small, nonrandomized efficacy cohort supports a randomized test of the combination. The added survival benefit remains an open question.
Tebentafusp (KIMMTRAK) recruits T cells through CD3 to recognize a gp100 peptide presented by HLA-A*02:01. Investigational brenetafusp uses a similar approach to recognize a PRAME peptide. The combination tests whether directing T cells toward two different tumor-associated peptides can improve outcomes in a rare eye cancer once it spreads. Tebentafusp has an FDA approval for HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma and randomized evidence of a survival benefit. The combination remains investigational.
In the 17-patient first-line group, the objective response rate was 29% and the median response duration was 24.1 months among responders. Median progression-free survival was 8.1 months. At 29 months of median follow-up, median overall survival was still unreached. The brenetafusp monotherapy results came from patients treated in the second line or later, a different clinical setting that cannot isolate the effect of adding brenetafusp to tebentafusp.
Across all 26 combination recipients, 77% had cytokine release syndrome (CRS), reported as grade 1 or 2. Grade 3 or 4 treatment-related adverse events occurred in 38%. A transient fall in lymphocyte counts was the most frequent of these higher-grade events. Immunocore reported zero treatment-related deaths or discontinuations. The small safety population limits what can be learned about uncommon toxicities.
What this means for trial teams
What the randomized trial can clarify. Immunocore plans DUET-UVEAL, a randomized Phase 2/3 trial. The question is how much clinical benefit the second engager adds and what treatment burden comes with it. For a rare cancer, a durable benefit over established care could change the first-line pathway for eligible patients. It could also justify testing other pairs of T-cell engagers in solid tumors, with each tumor and combination requiring its own evidence.
Separate molecular eligibility from access. HLA-A*02:01 prevalence varies across ancestry groups. Sponsors can measure referral-to-test turnaround and distinguish patients who lacked the required allele from those whose tests were delayed or never completed. That distinction helps teams see where faster referrals, easier sample collection or travel support could change who gets screened.
Plan for early infusions and long follow-up. The early study used weekly intravenous infusions with step-up dosing. Before activation, site teams can walk through how they will staff observation, document infusion and symptom onset times, and escalate suspected CRS under the study protocol. The FDA-approved tebentafusp label carries a boxed warning for CRS and specifies at least 16 hours of monitoring after each of the first three infusions. The combination study’s protocol governs its own procedures.
At Lampgen Clinical Research, we assess oncology CRA fit against the work a protocol requires. Here that means verifying the HLA report against eligibility, reconciling infusion and safety records, and checking how sites will document subsequent therapies and follow vital status after treatment ends. Those records help trial teams interpret the eventual survival comparison and understand the experience of the patients who enrolled.
Sources
- Immunocore | Phase 1/2 combination data presented at SITC, November 6, 2026
- ClinicalTrials.gov | Phase 1/2 study NCT04262466
- FDA | KIMMTRAK prescribing information
- New England Journal of Medicine | Three-year survival in the randomized tebentafusp trial
- JAMA Network Open | Eligibility for HLA-based therapies by race and ethnicity
- Related Lampgen insight | Clinical trial participation burden and patient access
- Lampgen | Oncology CRA staffing